Dr Vera Grinkevich | Postdoctoral Fellow

This person is a member of Sanger Institute Alumni.

Grinkevich, Vera

Resistance to chemotherapeutic and targeted anticancer drugs is one of the major causes for the lethal cancer progression. Genetic alterations (point mutations, amplifications and deletions) in the genomic DNA are the major causes of the both intrinsic and acquired resistance. Genome-wide CRISPR screens allow us to create a population of cells with single deletions covering whole human genome. Using cancer cell lines of different origin and current cancer treatments we perform resistance and sensitivity screens. This lets us to uncover the pathways which lead to cancer drug resistance, cancer sensitivity and understand better biology of cancer cells.

TOOLS

GeneSpy - Simple and fast gene-protein visualisation, gRNA and template design.

http://genespy.genescripts.org

Publications

  • Ablation of key oncogenic pathways by RITA-reactivated p53 is required for efficient apoptosis.

    Grinkevich VV, Nikulenkov F, Shi Y, Enge M, Bao W et al.

    Cancer cell 2009;15;5;441-53

  • Inhibition of glycolytic enzymes mediated by pharmacologically activated p53: targeting Warburg effect to fight cancer.

    Zawacka-Pankau J, Grinkevich VV, Hünten S, Nikulenkov F, Gluch A et al.

    The Journal of biological chemistry 2011;286;48;41600-15

  • Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA.

    Zhao CY, Grinkevich VV, Nikulenkov F, Bao W and Selivanova G

    Cell cycle (Georgetown, Tex.) 2010;9;9;1847-55

  • Inhibition of glycolytic enzymes mediated by pharmacologically activated p53: targeting Warburg effect to fight cancer.

    Zawacka-Pankau J, Grinkevich VV, Hünten S, Nikulenkov F, Gluch A et al.

    The Journal of biological chemistry 2011;286;48;41600-15

  • Abrogation of Wip1 expression by RITA-activated p53 potentiates apoptosis induction via activation of ATM and inhibition of HdmX.

    Spinnler C, Hedström E, Li H, de Lange J, Nikulenkov F et al.

    Cell death and differentiation 2011;18;11;1736-45

  • Learning-induced lateralized activation of the MAPK/ERK cascade in identified neurons of the food-aversion network in the mollusk Helix lucorum.

    Kharchenko OA, Grinkevich VV, Vorobiova OV and Grinkevich LN

    Neurobiology of learning and memory 2010;94;2;158-66

  • Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA.

    Zhao CY, Grinkevich VV, Nikulenkov F, Bao W and Selivanova G

    Cell cycle (Georgetown, Tex.) 2010;9;9;1847-55

  • Ablation of key oncogenic pathways by RITA-reactivated p53 is required for efficient apoptosis.

    Grinkevich VV, Nikulenkov F, Shi Y, Enge M, Bao W et al.

    Cancer cell 2009;15;5;441-53

  • The structure of p53 tumour suppressor protein reveals the basis for its functional plasticity.

    Okorokov AL, Sherman MB, Plisson C, Grinkevich V, Sigmundsson K et al.

    The EMBO journal 2006;25;21;5191-200

Career/Research Highlights

Grinkevich, Vera
Vera's Timeline
2014

Joined WTSI Sanger Insititute as a PostDoc, Cancer Genome Project.

2012

Started EMBO PostDoc, Department of Molecular BIology, Siena University, Italy.

2011

Received PhD at Karolinska Institute, Department of Microbiology, Tumour and Cell biology, Sweden.

2004

Master's Degree in Genetics St.Petersburg State University, Russia. Thesis at Cytology Institute.

2002

Bachelor's degree in Biology, St.Petersburg State University, Russia Thesis at Cytology Institute.

1996

Finished school-colledge 130, Novosibirsk, Russia.